Nalaganje...
Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies
Dipeptidyl peptidase 4 (DPP4) inhibitors have been touted as promising antihyperglycemic agents due to their beneficial effects on glycemia without inducing hypoglycemia or body weight gain and their good tolerability. Beyond their glucose-lowering effects, numerous clinical trials and experimental...
Shranjeno v:
| izdano v: | Diabetes Metab J |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Korean Diabetes Association
2015
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4641966/ https://ncbi.nlm.nih.gov/pubmed/26566494 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4093/dmj.2015.39.5.373 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|